Refined models of New Delhi metallo-beta-lactamase-1 with inhibitors: an QM/MM modeling study

J Biomol Struct Dyn. 2016 Oct;34(10):2214-23. doi: 10.1080/07391102.2015.1110834. Epub 2016 Jan 6.

Abstract

New Delhi metallo-beta-lactamase 1 (NDM-1) has been identified as a potential target for the treatment of multi-drug resistance bacterial infections. We used molecular docking, normal MD, SIE, QM/MM MD simulations, QM/MM GBSA binding free energy, and QM/MM GBSA alanine-scanning mutagenesis techniques to investigate interactions of the NDM-1 with 11 inhibitors (Tigecycline, BAL30072, D-captopril, Penicillin G, Ampicillin, Carbenicillin, Cephalexin, Cefaclor, Nitrocefin, Meropenem, and Imipenem). From our normal MD and QM/MM simulations, the correlation coefficients between the predicted binding free energies and experimental values are .88 and .93, respectively. Then simulations, which combined QM/MM/GBSA and alanine-scanning mutagenesis techniques, were performed and our results show that two residues (Lys211 and His250) have the strongest impact on the binding affinities of the 11 NDM-1/inhibitors. Therefore, our approach theoretically suggests that the two residues (Lys211 and His250) are responsible for the selectivity of NDM-1 associated inhibitors.

Keywords: New Delhi metallo-beta-lactamase 1; alanine-scanning mutagenesis; molecular docking; muti-drugs resistance; quantum mechanics/molecular mechanics molecular dynamics.

MeSH terms

  • Drug Design*
  • Models, Molecular*
  • Molecular Conformation
  • Molecular Docking Simulation
  • Molecular Dynamics Simulation
  • Mutation
  • Protein Binding
  • Quantitative Structure-Activity Relationship*
  • beta-Lactamase Inhibitors / chemistry*
  • beta-Lactamase Inhibitors / pharmacology
  • beta-Lactamases / chemistry*
  • beta-Lactamases / genetics

Substances

  • beta-Lactamase Inhibitors
  • beta-Lactamases
  • beta-lactamase NDM-1